201 related articles for article (PubMed ID: 10992272)
1. Effect of iron salts, haemosiderins, and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay.
Anderson D; Yardley-Jones A; Vives-Bauza C; Chua-Anusorn W; Cole C; Webb J
Teratog Carcinog Mutagen; 2000; 20(5):251-64. PubMed ID: 10992272
[TBL] [Abstract][Full Text] [Related]
2. Effects of iron salts and haemosiderin from a thalassaemia patient on oxygen radical damage as measured in the comet assay.
Anderson D; Yardley-Jones A; Hambly RJ; Vives-Bauza C; Smykatz-Kloss V; Chua-Anusorn W; Webb J
Teratog Carcinog Mutagen; 2000; 20(1):11-26. PubMed ID: 10607374
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of different thalassaemia genotypes to food mutagens in the Comet assay.
Ruf AA; Jerwood D; Webb J; Anderson D
Teratog Carcinog Mutagen; 2003; Suppl 2():83-91. PubMed ID: 14691982
[TBL] [Abstract][Full Text] [Related]
4. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of iron overload in thalassaemic patients.
Ceci A; Felisi M; De Sanctis V; De Mattia D
Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
[TBL] [Abstract][Full Text] [Related]
7. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
[TBL] [Abstract][Full Text] [Related]
8. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
Mourad FH; Hoffbrand AV; Sheikh-Taha M; Koussa S; Khoriaty AI; Taher A
Br J Haematol; 2003 Apr; 121(1):187-9. PubMed ID: 12670352
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP
Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920
[TBL] [Abstract][Full Text] [Related]
10. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
[TBL] [Abstract][Full Text] [Related]
11. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
[TBL] [Abstract][Full Text] [Related]
12. Oral deferiprone for iron chelation in people with thalassaemia.
Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
[TBL] [Abstract][Full Text] [Related]
13. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
14. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand.
Pootrakul P; Sirankapracha P; Sankote J; Kachintorn U; Maungsub W; Sriphen K; Thakernpol K; Atisuk K; Fucharoen S; Chantraluksri U; Shalev O; Hoffbrand AV
Br J Haematol; 2003 Jul; 122(2):305-10. PubMed ID: 12846901
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
Marshall R; Tricta F; Galanello R; Leoni G; Kirkland D; Minto S; Spino M
Mutagenesis; 2003 Sep; 18(5):457-63. PubMed ID: 12960415
[TBL] [Abstract][Full Text] [Related]
17. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
Fischer R; Longo F; Nielsen P; Engelhardt R; Hider RC; Piga A
Br J Haematol; 2003 Jun; 121(6):938-48. PubMed ID: 12786807
[TBL] [Abstract][Full Text] [Related]
18. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Ballas S; Steinberg MH; Rigano P; Sacco M; Telfer P; Renda D; Barone R; Maggio A;
Blood Cells Mol Dis; 2014 Dec; 53(4):265-71. PubMed ID: 24814618
[TBL] [Abstract][Full Text] [Related]
19. The role of anaemia in oxidative and genotoxic damage in transfused β-thalassaemic patients.
Ferro E; Visalli G; La Rosa MA; Civa R; Papa GR; D'Ascola DG; Roccamo G; Piraino B; Salpietro C; Di Pietro A
Hematology; 2017 Apr; 22(3):183-191. PubMed ID: 27801288
[TBL] [Abstract][Full Text] [Related]
20. Effect of antioxidant flavonoids and a food mutagen on lymphocytes of a thalassemia patient without chelation therapy in the Comet assay.
Anderson D; Dhawan A; Yardley-Jones A; Ioannides C; Webb J
Teratog Carcinog Mutagen; 2001; 21(2):165-74. PubMed ID: 11223893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
